Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
Michael J. P. Crowley et al.
Summary: IRE1 alpha-XBP1 signaling is crucial for malignant progression and immunosuppression in different cancers. XBP1s mRNA isoform expression predicts poor survival in NSCLC patients. Inhibition of IRE1 alpha delays tumor progression, prolongs survival, and induces adaptive anti-cancer immunity in mouse models of NSCLC. IRE1 alpha activation in cancer cells regulates mPGES-1 expression, leading to the production of immunosuppressive prostaglandin E-2. Targeting the IRE1 alpha pathway may enhance anti-tumor immunity in NSCLC.
NATURE COMMUNICATIONS
(2023)
Article
Multidisciplinary Sciences
Xiangdong Lv et al.
Summary: Proteostasis reprogramming is identified as a key convergence point of multiple mechanisms of resistance to mutant KRAS inhibitors. The reactivation of IRE1a, in an ER stress-independent manner, restores proteostasis in acquired KRAS inhibitor-resistant tumors. IRE1a phosphorylation and stability are promoted by reactivated ERK and hyperactivated AKT, which can be overcome by suppressing IRE1a.
Article
Multidisciplinary Sciences
Yulei Zhao et al.
Summary: Resistance to KRAS(G12C) inhibitors demonstrates a heterogeneous pattern with multiple subclonal events emerging during treatment. Co-targeting of ERK signaling intermediates can enhance the antiproliferative effect of G12C inhibitor treatment in models with acquired RAS or BRAF mutations.
Article
Medicine, Research & Experimental
Iwao Shimomura et al.
Summary: The study found that verteporfin can effectively inhibit the viability of KRAS-mutant lung cancer cells and suppress KRAS-driven lung tumors. The mechanism of verteporfin action is partially independent of YAP1 inhibition and leads to apoptotic cell death in KRAS-mutant lung cancer cells by inducing endoplasmic reticulum stress pathway.
Article
Medicine, General & Internal
M. M. Awad et al.
Summary: A study of 38 patients with KRAS(G12C)-mutant cancers treated with adagrasib revealed diverse mechanisms of acquired resistance in 45% of them, including various mutations and bypass mechanisms. New therapeutic strategies are needed to overcome this drug resistance.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
